Pharma R&D
Pharma R&D
Pharma R&D
Pharma R&D
Directors & Senior Staff
Bernie Romanin
Chief Executive Officer and Director
B App Sci and Grad Dip Marketing
Bernie Romanin has extensive healthcare experience in Diagnostics, Pharmaceuticals, Healthcare Bioinformatics and Medical Devices gained in Australia and internationally including commercial expertise (sales, marketing and business development) spanning more than 35 years.
During almost a decade in the USA with Chiron, Novartis and Bayer he has directed market development activities to identify, validate and commercialise new opportunities in diagnostics in the areas of Infectious Diseases (Hepatitis and HIV/AIDS), Oncology, Cardiovascular Disease and Metabolic Disorders.
Bernie has significant experience in managing start-up and new market business opportunities particularly in Technology Licensing and Partnerships and broad experience in managing a multi-functional organisation including R&D, sales and marketing, business development and market research.
Dr. Robyn A. Lindley
Chief Scientific Officer and Director
Inventor and Developer of the TSM Platform.
BSc, MInfoTech, PhD
Dr Robyn A. Lindley is a Founder, Director and the Chief Scientific Officer of GMDx Genomics, Melbourne. She is also an Honorary Senior Fellow in the Department of Pathology, Faculty of Medicine, Dentistry and Health Sciences at the University of Melbourne.
Although her first degrees are in physics and informatics, Robyn is an immunogeneticist who has been publishing on the relationships between inflammation, disease progression and somatic mutation signatures. Robyn is the sole discoverer of the specific codon-contexted targeted somatic mutation (TSM) signatures of nucleotide-specific deaminase enzymes that are now heavily implicated in many cancers. She was also the first to show that some of these changes can be used to predict cancer progression. She was the recipient of the RD Wright medal in 2016, University of Melbourne, for 'marching to the beat of her own drum'. Robyn's foundation research is now being used to develop new genetic tests to predict patient response to
immuno-oncology drugs and cancer progression for use in the North American market.
Cameron Jones
Chief Financial Officer & Company Secretary
CFO, CoSec
Cameron is the Managing Director of Bio101, a financial services firm providing accounting, tax and company secretarial services specialising in the healthcare and life science sectors. A qualified Chartered Accountant and registered tax agent, Cameron acts as CFO and Company Secretary for a number of ASX listed and Venture Capital investee companies. Cameron has assisted a number of companies through the Initial Public Offering (IPO) process, capital raisings and M&A transactions. Cameron is also a Director and Treasurer of registered charities Cystic Fibrosis Community Care Ltd (CFCC) and BioAutism Ltd and Chair of the Investment Committee for CFCC.
Richard Rendell
Chief Technology Officer
An accomplished Melbourne-based company director and CEO with 18 year’s experience in healthcare, precision medicine, life-sciences, information technology, M&A, investment, commercialisation, globalisation and compliance. Richard has recently been covered in Forbes magazine regarding his company Applied Precision Medicine, one of a portfolio of 4 companies he has created over a 7 year period. His success in Healthcare, Medical Device, and Digital Health sectors showcases an ability to identify and pursue emerging markets using proven adaptive business models under strong compliance and governance. At Oracle Corporation, Richard owned several product divisions with responsibility for global strategy in sales, marketing, consulting, product development, education and support. He led technical and commercial due diligence in many Oracle acquisitions. Richard is also media trained and has worked with journalists in the United States and Australia. Richard was an advisory board founder at iSelect Pty Ltd where he returned in 2008 as CIO to deliver significant business restructuring to support new insurance markets building iSelect’s next chapter in digital strategy. iSelect listed on the ASX in June 2013 at a value of AU$300M.
Dr. Nathan Hall
Genomics & Platform Lead
Senior Scientist
BSc(Hons), PhD
Dr. Nathan Hall is an accomplished researcher with expertise in bioinformatics, computational biology and genomics sciences. His background is in biomedical research, starting out his career over twenty years ago when genomes were only beginning to be sequenced. Nathan collaborates widely and is published in areas such as Cancer research and genomic analyses.
Nathan understands the importance of integrating computational biology with medical and scientific research to maximise the benefits of modern sequencing technologies. With this understanding of the power of genomic technology, Nathan is engaging with Medical Practitioners, laboratory scientist and researchers, and computational professionals to bring together a platform for genomic testing moving into the future.
Dr. Jared Mamrot
Bioinformatician
BSc(Hons), MCE, PhD
Dr. Mamrot is a bioinformatician/data scientist who completed his PhD in developmental genomics at the Hudson Institute of Medical Research in Victoria, Australia. He has experience developing novel computational pipelines and applying innovative methods to complex biological challenges. He is an active member of the scientific community and is an ambassador for reproducibility and open science initiatives for the journal eLife and protocols.io.
At GMDx, he is applying state-of-the-art artificial intelligence / machine learning methods to drive scientific advances in immunology and oncology. He is currently heading the machine learning program developing novel approaches to predict patient response to treatments for many diseases.